Skip to Content

Cystadrops FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 27, 2020.

FDA Approved: Yes (First approved August 19, 2020)
Brand name: Cystadrops
Generic name: cysteamine hydrochloride
Dosage form: Ophthalmic Solution
Company: Recordati Rare Diseases Inc.
Treatment for: Corneal Cystine Crystal Accumulation

Cystadrops (cysteamine hydrochloride) is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis.